BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial. To access the advisory, go to the following link: http://www.regenerx.com/2020-04-20-Ap

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has received a Notice of Allowance for its second composition matter patent to be awarded by the Canadian Intellectual Property Office. This ne

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the record date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. (“Hoth”) is April 30, 2020 , and the Company is currently working to determine the date of distribution.

Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS ® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 - Global study to enroll approximately 270 adults with COVID-19 and severe pneumonia or acute respiratory distress syndrome - - Company maintains commitment to supplying its medicines to patients for currently approved indications -

Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company’s ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.

RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide its investigational drug, RHB-107 (upamostat, WX-671) 1 , for testing in non-clinical studies for activity against SARS-CoV-2,

Protech Home Medical Corp. (the “Company” or “Protech”) (TSXV: PTQ), a healthcare services company with operations in the U.S., is pleased to announce that it has been approved for a CAD$5.97 million loan under the Payroll Protection Program (“PPP”) administered by the U.S. Small Business Administration.

The Leona M. and Harry B. Helmsley Charitable Trust announced today a multimillion-dollar effort to save the lives of COVID-19 patients and protect the frontline healthcare workers caring for them.

Conformis, Inc. (NASDAQ:CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West Bank (NASDAQ:EWBC) under the Paycheck Protection Program (“PPP”) offered by the U.S. Small Business Administration (the “SBA”) to mitigate the negative financial and operational impacts of the coronavirus (COVID-19) pandemic.

The partnership will support verification and clinical validation of RT-PCR tests to detect the COVID-19 virus.